ATNF - 180 Life Sciences Corp. Stock Price, Fair Value and News

$1.86-0.08 (-4.12%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ATNF Price Action

Last 7 days

-3.6%

Last 30 days

-20.5%

Last 90 days

-5.6%

Trailing 12 Months

-42.1%

ATNF RSI Chart

ATNF Valuation

Market Cap

3.7M

Price/Earnings (Trailing)

-1.18

Price/Sales (Trailing)

190.49

EV/EBITDA

-0.05

Price/Free Cashflow

-1.37

ATNF Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ATNF Fundamentals

ATNF Revenue

Revenue (TTM)

25.9K

ATNF Earnings

Earnings (TTM)

-3.1M

Earnings Growth (Yr)

91.85%

Earnings Growth (Qtr)

-7.2K%

ATNF Profitability

EBT Margin

-12048.78%

Return on Equity

-83.61%

Return on Assets

-29.82%

Free Cashflow Yield

-73.15%

ATNF Investor Care

Shares Dilution (1Y)

402.48%

Diluted EPS (TTM)

7.32

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	0	0	0	0
2021	0	0	0	0
2020	0	0	0	0
2019	0	0	0	25.9K
2017	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About 180 Life Sciences Corp.

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

CEO	Dr. James N. Woody M.D., Ph.D.
WEBSITE	https://180lifesciences.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	5

180 Life Sciences Corp. Frequently Asked Questions

What is the ticker symbol for 180 Life Sciences Corp.? What does ATNF stand for in stocks?

ATNF is the stock ticker symbol of 180 Life Sciences Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 180 Life Sciences Corp. (ATNF)?

As of Fri Dec 20 2024, market cap of 180 Life Sciences Corp. is 3.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATNF stock?

You can check ATNF's fair value in chart for subscribers.

Is 180 Life Sciences Corp. a good stock to buy?

The fair value guage provides a quick view whether ATNF is over valued or under valued. Whether 180 Life Sciences Corp. is cheap or expensive depends on the assumptions which impact 180 Life Sciences Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATNF.

What is 180 Life Sciences Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, ATNF's PE ratio (Price to Earnings) is -1.18 and Price to Sales (PS) ratio is 190.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATNF PE ratio will change depending on the future growth rate expectations of investors.